Network Security Internet Technology Development Database Servers Mobile Phone Android Software Apple Software Computer Software News IT Information

In addition to Weibo, there is also WeChat

Please pay attention

WeChat public account

Shulou

The first domestic proton therapy system has been approved to be put on the market, and the localization of high-end medical equipment in China has been further improved.

2025-01-31 Update From: SLTechnology News&Howtos shulou NAV: SLTechnology News&Howtos > IT Information >

Share

Shulou(Shulou.com)11/24 Report--

CTOnews.com Sept. 26, today, the State Drug Administration approved the application for registration of "proton therapy system" innovative products produced by Shanghai Epuqiang Particle equipment Co., Ltd. This marks another step forward in the localization of high-end medical equipment in China, and is of great significance to improve the means and level of medical oncology diagnosis and treatment in our country.

CTOnews.com learned that this product is the key support project of the Ministry of Science and Technology's key research and development program "Digital diagnosis and treatment equipment Project" during the 13th five-year Plan period, and it is also the first domestic proton therapy system approved to be put on the market in China.

On September 26, 2022, the State Drug Administration approved the application for registration of "proton therapy system" innovative products produced by Shanghai Epuqiang Particle equipment Co., Ltd. This product is the key support project of "Digital diagnosis and treatment equipment Project", which is the key research and development plan of the Ministry of Science and Technology during the 13th five-year Plan period. It is also the first domestic proton therapy system approved to be listed in China. The approval of this product on the market marks another step in the localization of high-end medical equipment in China, and is of great significance to improve the means and level of medical oncology diagnosis and treatment in our country.

The product consists of two parts: accelerator system and treatment system. The accelerator system includes injector system, low energy transmission system, main accelerator system, high energy beam transmission system and auxiliary electrical system. The treatment system includes fixed beam therapy system, 180 °rotating beam therapy system and treatment planning system. The product provides proton beam for radiotherapy, which can not only achieve a high dose at the tumor site, but also reduce the dose of the surrounding normal tissue, especially the tissue behind the target area, which is suitable for the treatment of systemic solid malignant tumors and some benign diseases. the specific indications should be determined by clinicians according to the actual situation.

Users shall use the product strictly in accordance with the scope of application approved by the product, and at the same time strictly abide by the diagnosis and treatment standards of the health department.

In the process of registration and application of the product, the State Drug Administration, in accordance with the principle of "intervention in advance, special responsibility, guidance for the whole process, and scientific examination and approval", actively communicate and coordinate with each other under the premise of no reduction in standards and procedures, increase guidance for product registration, speed up the process of examination and approval, promote products on the market as soon as possible on the basis of ensuring safety and effectiveness, and meet the needs of patients for using high-level medical devices.

Established in June 2011, Shanghai Aipuqiang Particle equipment Co., Ltd. is a proton radiotherapy equipment industrialization company for the Chinese market controlled by Shanghai Lianhe Investment Co., Ltd., a wholly state-owned company in Shanghai. 36% of the company's personnel have a master's degree, and 28% have a doctor's degree.

According to reports, the proton radiotherapy equipment of the tumor Proton Center of Ruijin Hospital affiliated to the Medical College of Shanghai Jiaotong University will carry out clinical trials in November 2021.

On November 30, 2021, the eighth commander's meeting and clinical trial launching ceremony for the development of the first domestic proton therapy demonstration device was held in Shanghai Ruijin Cancer (Proton) Center. Academician Ning Guang, dean of Ruijin Hospital affiliated to Medical College of Shanghai Jiaotong University, Academician Zhao Zhentang, director of Shanghai Light Source Science Center and chief scientist of the first domestic proton therapy demonstration device, Dai Zhimin, director of Shanghai Institute of Applied Physics, Chinese Academy of Sciences, Sun Xidong, vice president of Shanghai Lianhe Investment Co., Ltd., chairman and general manager of Shanghai Aipuqiang Particle equipment Co., Ltd. As well as the Shanghai Proton Therapy equipment Project Construction team and Ruijin Hospital medical team related equipment, physics, medical and other experts attended the launching ceremony. The meeting was presided over by Chen Haitao, vice president of Ruijin Hospital.

Chen Zhiling, deputy chief engineer of the treatment system of Shanghai Proton Therapy device, introduced the preparation of the clinical trial project of the first domestic proton therapy device. Chen Jiayi, director of the radiotherapy department of Ruijin Hospital, introduced the basic situation and treatment plan of the first two patients who met the clinical trial of proton therapy after screening. Academician Ningguang and Zhao Zhentang announced the official launch of the clinical trial of the first domestic proton therapy device. Director Dai Zhimin and Chairman Sun Xidong expressed congratulations on the launch of the clinical trial and thanked the project and the medical team. After that, two subjects (one patient with recurrent pituitary adenoma and one patient with recurrent chordoma of skull base) who were enrolled in the first domestic proton clinical trial received the first proton radiotherapy. Both subjects had no complaints after treatment.

On the morning of December 15, 2021, after 12 sessions of treatment, the first patient finished all treatment, and the patient needed 3 months of short-term and 5-year long-term observation. The treatment of the second patient will also end next week. There was no discomfort in both patients.

Welcome to subscribe "Shulou Technology Information " to get latest news, interesting things and hot topics in the IT industry, and controls the hottest and latest Internet news, technology news and IT industry trends.

Views: 0

*The comments in the above article only represent the author's personal views and do not represent the views and positions of this website. If you have more insights, please feel free to contribute and share.

Share To

IT Information

Wechat

© 2024 shulou.com SLNews company. All rights reserved.

12
Report